Medacta Corporate
GMK Primary awarded 3A* ODEP rating, confirming excellent survival rate of the implant

GMK Primary awarded 3A* ODEP rating, confirming excellent survival rate of the implant

Medacta is constantly committed to provide innovative and safe products. The Orthopaedic Data Evaluation Panel (ODEP) has recently confirmed this commitment by awarding GMK Primary a 3A* rating.

According to the ODEP rating criteria, Medacta GMK Primary has been evaluated in a minimum cohort of 150 knees at 3 years, demonstrating Kaplan-Meier survivorship data in line with the highest ODEP standards for total knee arthroplasty.

The Medacta strategy is – and has always been – centered on innovation and education. 
Innovation has allowed Medacta to continue providing original and unique products with exceptional outcomes and value for patients and healthcare systems around the world. 
Through medical education provided by the Medacta Orthopaedic Research and Education (M.O.R.E.) Institute, Medacta supports professionals in the field of research and education, improving patient outcomes with effective surgeon training programs, and surgeon-to-surgeon educational opportunities with the sharing of best practices and clinical experience.
 
Read more on GMK Primary.